Semaglutide D Dose 1
DrugTablet given orally
NCT Number: NCT05227196
The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood in two different tablet versions of Semaglutide. The study will consist of 3 groups and the treatment the participants will get is dependent on the group the participants will be enrolled in.
The participants in group 1 will receive treatment for 22 weeks, group 2 for 21 weeks and group 3 for 20 weeks.
The study will last up to 29 to 31 weeks for each participant. This includes a screening period (up to 4 weeks), a dose escalation period (up to 2 weeks), a treatment period (20 weeks) and a follow-up period (5 weeks after the last dose).
Looking for future studies?
Notify Me18 year–64 year
All sexes
Interventional
Phase 1
Altasciences Company Inc., Montreal, Quebec, Canada
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Tablet given orally
Tablet given orally
Tablet given orally
Tablet given orally
Tablet given orally
Tablet given orally
Time frame: 24 hours after the dosing of oral semaglutide on days 35/42/49, 70/77/84, 105/112/119 and 140/147/154.
h∙nmol/L
Time frame: 24 hours after the dosing of oral semaglutide on days 35/42/49, 70/77/84, 105/112/119 and 140/147/154.
nmol/L
Time frame: 24 hours after the dosing of oral semaglutide on days 35/42/49, 70/77/84, 105/112/119 and 140/147/154.
h
Time frame: 24 hours after the dosing of oral semaglutide on days 35/42/49, 70/77/84, 105/112/119 and 140/147/154.
nmol/L
Novo Nordisk A/S
Industry
A Bioequivalence Study of Two Formulations of Oral Semaglutide in Healthy Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05521256
Diabetes Mellitus, Diabetes Mellitus, Type 2
Neuss, North Rhine-Westphalia, Germany
View Trial DetailsNCT05129891
Diabetes Mellitus, Diabetes Mellitus, Type 2
Montreal, Quebec, Canada
View Trial DetailsNCT04676906
Diabetes Mellitus, Diabetes Mellitus, Type 2
Groningen, Netherlands
View Trial DetailsNCT04097600
Diabetes Mellitus, Diabetes Mellitus, Type 2
Berlin, Germany
View Trial Details